Islam MS, Gurley ES, Banu S, et al. Prevalence and incidence of tuberculosis infection among healthcare workers in chest diseases hospitals, Bangladesh: Putting infection control into context. PLoS One. 2023;18(9):e0291484. Published 2023 Sep 27. doi:10.1371/journal.pone.0291484
Publication Category: Clinical
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis
Krishnan S, Wu X, Kim S, et al. 1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2023;77(6):892-900. doi:10.1093/cid/ciad301
Glycated Hemoglobin Trajectories and Their Association With Treatment Outcomes Among Patients With Pulmonary TB in India: A Prospective Cohort Study
Pardeshi G, Mave V, Gaikwad S, Kadam D, Barthwal M, Gupte N, Atre S, Deshmukh S, Golub JE, Gupte A. Glycated Hemoglobin Trajectories and Their Association With Treatment Outcomes Among Patients With Pulmonary TB in India: A Prospective Cohort Study. Chest. 2024 Feb;165(2):278-287. doi: 10.1016/j.chest.2023.08.026. Epub 2023 Sep 4. PMID: 37673207; PMCID: PMC10851276.
Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing
Malhotra A, Thompson R, De Vos M, David A, Schumacher S, Sohn H. Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing. PLoS One. 2023 Aug 24;18(8):e0290496. doi: 10.1371/journal.pone.0290496. PMID: 37616318; PMCID: PMC10449112.
Modeling the impact of universal tuberculosis molecular testing and timing of tuberculosis preventive treatment during antiretroviral therapy initiation in South Africa
Balasubramanian R, Shearer K, Mudzengi D, Hippner P, Golub JE, Chihota V, Hoffmann CJ, Kendall EA. Modeling the impact of universal tuberculosis molecular testing and timing of tuberculosis preventive treatment during antiretroviral therapy initiation in South Africa. AIDS. 2023 Dec 1;37(15):2371-2379. doi: 10.1097/QAD.0000000000003707. Epub 2023 Aug 30. PMID: 37650763; PMCID: PMC10782927.
Undiagnosed Pulmonary Tuberculosis (TB) and Coronavirus Disease 2019 (COVID-19) in Adults Dying at Home in a High-TB-Burden Setting, Before and During Pandemic COVID-19: An Autopsy Study
Sabet N, Omar T, Milovanovic M, Magajane T, Mosala M, Moloantoa T, Kato-Kalule N, Semedo LV, Swanepoel F, Wallis C, Abraham P, Lebina L, Variava E, Martinson N. Undiagnosed Pulmonary Tuberculosis (TB) and Coronavirus Disease 2019 (COVID-19) in Adults Dying at Home in a High-TB-Burden Setting, Before and During Pandemic COVID-19: An Autopsy Study. Clin Infect Dis. 2023 Aug 14;77(3):453-459. doi: 10.1093/cid/ciad212. PMID: 37041678.
Comparative immune responses to Mycobacterium tuberculosis in people with latent infection or sterilizing protection
Jalbert E, Liu C, Mave V, Lang N, Kagal A, Valvi C, Paradkar M, Gupte N, Lokhande R, Bharadwaj R, Kulkarni V, Gupta A, Weinberg A.
QuantiFERON Supernatant-Based Host Biomarkers Predicting Progression to Active Tuberculosis Disease among Household Contacts of Tuberculosis Patients
Daniel EA, Thiruvengadam K, Rajamanickam A, Chandrasekaran P, Pattabiraman S, Bhanu B, Sivaprakasam A, Paradkar M, Kulkarni V, Karyakarte R, Shivakumar SVBY, Mave V, Gupta A, Babu S, Hanna LE.
Number Needed to Screen for Tuberculosis Disease Among Children: A Systematic Review
Robsky KO, Chaisson LH, Naufal F, Delgado-Barroso P, Alvarez-Manzo HS, Golub JE, Shapiro AE, Salazar-Austin N.
Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response
Peters JS, McIvor A, Papadopoulos AO, Masangana T, Gordhan BG, Waja Z, Otwombe K, Letutu M, Kamariza M, Sterling TR, Bertozzi CR, Martinson NA, Kana BD. Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response. Front Cell Infect Microbiol. 2023 Jan 12;12:1064148. doi: 10.3389/fcimb.2022.1064148. PMID: 36710965; PMCID: PMC9877613.